

# **EMERGING MARKETS:** Covid-19 Vaccination Strategies and Challenges

Our Covid-19 vaccination table includes updated information on the immunization strategies selected EMs are pursuing and the challenges they face.

Below are some of the latest developments. Please do not hesitate to contact us if you want to discuss any of the countries mentioned in more detail.

Click on 'View PDF' to see the table.

#### **HIGHLIGHTS**

#### Vaccine rollout

- In **Chile**, the Sinovac vaccine has been authorized for children as young as six (with parental consent); health authorities plan to start vaccinating this age cohort from late-September with inoculations taking place at schools.
- Colombia expects its first shipment of 1.2mn Moderna doses to arrive by the end of this week, with 4mn Moderna doses
  expected by the end of this month.
- Having fully vaccinated 50-58% of their populations, further vaccination progress in the Czech Republic, Hungary and Poland is extremely slow. However, rising infections in the region could at least partly reinvigorate their vaccination campaigns.
- **Mexico**'s government wants everyone over the age of 18 to have received at least one dose of a coronavirus vaccine by 31 October; the use of vaccines for the 16-18 age group could come under consideration after October.
- In **Poland**, around one-third of eligible school pupils in the 12-18 age group have been vaccinated since June.
- **South Africa**'s health products regulator SAHPRA has granted emergency approval for use of the Pfizer vaccine in children aged 12+, though for now, the vaccine rollout remains open to adults aged 18+.
- **Thailand**'s official vaccine regimen is now Sinovac for the first shot and AstraZeneca for the second to reduce the time between jabs to three weeks and extend supplies.
- Nigeria's vaccination campaign has recommenced following the arrival of new vaccine shipments in late August and early September.

#### Vaccine procurement

Teneo Macro 1

- Lack of access to vaccine supplies continues to be a major barrier preventing poorer countries from vaccinating their citizens. Last week, COVAX, a global program to ensure global vaccine access, announced that its 2021 forecast for available doses would be reduced by 25%.
- **Argentina** has received its first delivery of the Pfizer vaccine. Close to 20mn Pfizer doses are expected before the end of 2021; some of these will be administered to people who have been waiting for a second dose of the Sputnik V vaccine.
- Hungary started construction of a HUF 55bn (USD 185mn) vaccine production facility in Debrecen, which is expected
  to be launched by the end of 2022. It will have capacity to manufacture up to 20mn vaccine doses per annum, including
  Sinopharm's Covid-19 vaccines.
- **Kenya** is establishing a fill-and-finish facility for Covid-19 vaccines ahead of setting up a full-scale manufacturing plant to guarantee supply. Local production is expected to start during the first quarter of 2022.
- Peru's President Pedro Castillo last week announced that an agreement had been reached with the Russian Direct Investment Fund (RDIF) to set up a vaccine production facility in Peru; health authorities later clarified that discussions with the RDIF were underway and that any facility was unlikely to be up-and-running before 2023 at the earliest.
- Taiwan will send a senior foreign ministry official to lead an investment delegation to Slovakia, Czech Republic, and Lithuania to boost commercial ties with those three countries, which have collectively donated 60,000 vaccine doses to Taiwan.

#### Infections and new variants

- In **Brazil**, the Delta variant already represents 63% of the Covid-19 cases, and almost all of the remaining samples are from the Gamma variant (P1). Even with the progress of the variants, the number of cases continues to drop.
- Russia's infection and death levels from Covid-19 are likely to remain high due to relatively low vaccination levels and few
  restrictions in place. Colder weather and reopened schools could aggravate the epidemiological situation in the coming
  weeks.
- On 13 September, **South Africa**'s lockdown restrictions were eased to adjusted "Level 2" regulations thanks to a sustained fall in Covid-19 infections.

#### Vaccine diplomacy

- China will have donated 100mn vaccine doses to developing countries by the end of 2021, President Xi Jinping told a virtual summit of **Brazil**, **Russia**, **India**, and China. Through early September, China had already sold 1.2bn doses globally and donated a further 54mn, compared to **US** global donations of 128mn doses.
- **Kenya** is receiving donations of Pfizer, Moderna and AZ vaccines, including donations from the US of 1.76mn Moderna vaccines (already delivered) and 1.7mn Pfizer doses (expected later this month).
- Mexico has delivered 150,000 AstraZeneca (AZ) doses each to Honduras and Bolivia, and plans to donate vaccines to Jamaica, Paraguay, Belize, and Nicaragua, as part of its own sub-regional vaccine diplomacy efforts.

Macro Research +44 20 7186 8894 Macro@teneo.com

© 2021 Teneo. All rights reserved. This material was produced by Teneo for use solely by the recipient. This communication is intended as general background research and is not intended to constitute advice on any particular commercial investment or trade matter or issue and should not be relied upon for such purposes. The views expressed here represent opinions as of this date and are subject to change without notice. The information has been obtained from sources believed to be reliable but no guarantees can be given as to its accuracy, completeness or reliability. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or otherwise, without the prior consent of Teneo.

Teneo Macro 2



## **Emerging Markets Covid-19 Vaccination Strategies and Challenges**

### Rating of countries' vaccine rollout (as of 15 September 2021):

Between 0% and 10% of the total population have received at least one Covid-19 vaccine dose Between 10% and 30% of the total population have received at least one Covid-19 vaccine dose More than 30% of the total population have received at least one Covid-19 vaccine dose

	Vaccination strategy	Current state of vaccine roll-out	Procurement
Israel	As concern mounted about a surge in Delta variant-driven cases, Israel was the first to roll out a third dose, Pfizer booster and has progressively lowered the eligibility age (all Israelis over 12 with 5 months elapsed since second dose now qualify for a booster). And according to the health ministry, the country is moving ahead to ensure it has enough vaccines for a possible second round (fourth dose) of booster shots. In addition to Pfizer, Moderna is being used for those 18+. A lower dosage of Pfizer has been authorized for vulnerable children between 5-11 years old.	Israel has vaccinated 67% of its 9.3mn citizens with at least one dose, and 61% are fully vaccinated (majority have received Pfizer). 2.8mn people have received a third dose booster since August. Vaccine supply to West Bank and Gaza is making slow progress. More first doses have been administered in recent weeks: 25% have received a first dose, but the share of those fully vaccinated has ticked up only slightly to around 10%.	Pfizer-BioNTech – Israel administering Pfizer vaccine, in exchange for giving Pfizer extensive patient data. Another 1mn Pfizer doses to arrive in Sept. Moderna – Israel plans to vaccinate about 100,000 Palestinian workers with the Moderna vaccine. 500,000 doses arrived late August in West Bank and Gaza from the US (via COVAX). The Palestinian Authority has received more than 390,000 doses: 100,000 Sinopharm, 97,000 AZ SK Bio, 90,000 Sputnik V, 140,000 Pfizer-BioNTech and 2,000 Moderna, 25,000 AZ SII, and 48,000 AZ R-Pharm.
UAE	UAE has one of the highest immunization rates globally. Booster doses being administered for those who received second Sinopharm dose 6+ months ago; not yet required for other vaccines. The UAE encourages parents to vaccinate school-age children: Sinopharm is available for those 3+ and Pfizer for those 12+. From 30 Aug, the UAE began receiving tourists from all countries who have received both doses of a WHO-approved Covid-19 vaccine (a rapid test is still required on departure and arrival).	As of 14 Sept, 19mn doses have been administered. 92% of the UAE population has received a first dose, while 80% are fully vaccinated according to the health ministry.	Sinopharm, Sinovac, AZ, Covishield, J&J, Moderna and Pfizer-BioNTech are the WHO-approved vaccines that are accepted. UAE signed an agreement to produce Sinopharm domestically.
Chile	Target to vaccinate 80% of population over 16 years of age has been met. Medical workers were the first to receive vaccinations, followed by elderly in care homes; over 65s; key workers in public bureaucracy; people with other comorbidities. Offer of booster jabs also opened in Aug. As of mid-Sept, 14-17 year-olds receiving jabs.	Pfizer vaccinations started in late Dec but mass campaign using China's Sinovac vaccine started 3 Feb. As of 12 Sept, 14.5mn people (75.3% of population) have received at least one dose, while 13.9mn people (72.4% of the population) have been fully vaccinated. Campaign of booster jabs started in mid-Aug.	Pfizer-BioNTech – agreement for 10mn doses; Sinovac – agreement for 60mn doses over three years; AZ – agreement for 14.4mn doses.  COVAX – agreement for 8mn doses.  CanSino – agreement for 1.8mn doses.  J&J – regulatory clearance in early June.  Sputnik V - local regulatory clearance obtained late-Jul.
Hungary	Vaccination is available to all citizens aged 12+ years-old as well as foreigners living in Hungary. There is no official vaccination target. Starting Aug, third vaccine doses are available to citizens vaccinated four months ago or earlier.	Vaccination started on 26 Dec. As of 14 Sept, 5.84mn people (60.0% of population) have received at least one jab and 5.55mn (57%) have been fully immunized.	Procurement contracts and deliveries as of 14 Sept via the EU's joint mechanism:  AZ – 6.5mn doses (3.4mn delivered).  Moderna – 1.7mn doses (1.5mn delivered).  Pfizer-BioNTech – 10.9mn doses (8.5mn delivered).  J&J – 4.3mn doses (550,800 delivered).  National-level procurement:  Sputnik V – 2mn doses (delivered).  Sinopharm – 5mn doses (5.2mn delivered).
Singapore	Seniors, healthcare and frontline workers nominated by their employers were the first eligible groups. Starting in July, all residents 12 years and older are eligible to be vaccinated. Sinovac has been imported and allowed for distribution by some private clinics but is not being counted in the official vaccination count.	As of 12 Sept, 4.48mn (78.9% of population) have been fully vaccinated and 0.17mn (2.91% of population) have received at least one dose. Having reached its vaccination targets, Singapore is planning on lifting many restrictions and allowing some inbound travel in Q4.	Government has concluded agreements with three suppliers, with undisclosed quantities: Pfizer-BioNTech, Moderna and Arcturus. It has received CoronaVac and has allowed private purchases of the vaccine. It is looking for additional supplies in anticipation of possible shortfalls.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Poland	All residents aged 12+ years old are eligible for vaccination. Starting 1 Jul, vaccinated residents can participate in a state-run lottery. Discussions on mandatory vaccination are likely to pick up as the fourth wave of the pandemic is approaching. Third (booster) vaccine doses are currently available to people with immunodeficiency, but their availability will likely be expanded to other target groups such as seniors and health professionals in the coming weeks.	Vaccinations started on 27 Dec. As of 14 Sept, 19.5mn residents (51.2% of population) received a first jab and 19.1mn (50.1%) are fully vaccinated. The number of new vaccinations has dropped to just around 56,000 per week in early Sept (down from the peak of 1.2mn in early May).	Procurement exclusively via the EU. As of 14 Sept, 58.8mn vaccine doses delivered: 40.9mn <b>Pfizer-BioNTech</b> , 10.6mn <b>AZ</b> , 5.1mn <b>Moderna</b> , 2.2mn <b>J&amp;J</b> .
Greece	Currently offering vaccines to everyone over the age of 12 but is short of its target to vaccinate 70% of adults by the end of summer. The government has made it compulsory for hospital staff to be vaccinated. Non-vaccinated workers face suspension since 1 Sept. There are no firm plans to extend this to other parts of the civil service.	As of 14 Sept, 60.57% of the total population had received at least one jab and 56.48% are fully vaccinated. Daily vaccination rates dipped substantially during much of the summer, but they have started to rise again over the past few days, at roughly 20,000. Among over 60s, the vaccination uptake ranges between 72 and 85%.	Greece is using the <b>Pfizer-BioNTech</b> , <b>AZ</b> , <b>Moderna</b> and <b>J&amp;J</b> vaccines, adhering to the EU's procurement process. Next day appointments for vaccines are available in most parts of the country. Greece recently gifted 200,000 vaccines to Libya.
China	The Chinese Centre for Disease Control and Prevention (CDC) said vaccinating 80-85% of the population, or 1.1bn people, is required to reach herd immunity and that this level could be reached by end-2021.  The National Health Commission (NHC) has approved booster shots for vulnerable populations. New study shows that using a different vaccine as booster may be more effective than a third dose of <b>Sinovac</b> .	By 6 Sept, 970mn people, or 67% of the population, was fully vaccinated. and 1.09bn, or 76% of the population, had received at least one dose. The NHC says that 76% of the population, could be fully vaccinated by the end of October, but NHC also warned that it is becoming more difficult to persuade the remaining holdouts.	Regulators have approved five domestic vaccines; Sinopharm Beijing, Sinopharm Wuhan, CanSino Biologics, Sinovac Biotech, and Anhui Zhifei Longcom Biopharmaceuticals.  Fosun Pharmaceutical has contract to distribute and produce Pfizer-BioNTech vaccine and is waiting for mainland regulators to approve.
Saudi Arabia	587+ vaccine centers across the country. Mix of vaccines approved for 2 separate doses. Moderna approved for 12-17 year olds. Employees can be dismissed from employment for refusal to get vaccinated, individuals can be arrested for violating quarantines, and businesses fined for violating preventive measures. Vaccination mandatory to enter commercial and govt spaces (since 1 Aug). From 23 Sept, period of institutional quarantine reduced to 5 days for partially or unvaccinated visitors.	The vaccination program began on 17 Dec. As of 14 Sept, 67% of the population has received at least one dose and 50% are fully vaccinated.	Pfizer-BioNTech, Moderna, J&J, and AZ approved for administration. Sinovac and Sinopharm have just been approved.  Sputnik V is not accepted or approved by Saudi Arabia for travelers visiting the Kingdom.  KSA signing MoUs in Sept with AZ and Pfizer to manufacture vaccines locally.
Czech Republic	Since 1 Jul, all residents of 12+ years old are eligible for vaccination. The government has set up vaccination centers that allow residents to show up without pre-registering. Registration for third (booster) vaccine dose will start on 20 Sept and will be available to persons who have received their second/last dose eight months ago or earlier.	Vaccinations started on 27 Dec. As of 14 Sept, 5.8mn residents (53.6% of population) have received a first jab and 5.63mn (52.6%) were fully immunized. 82.8% of immunizations carried out with Pfizer-BioNTech vaccine; 7.6% with AZ; 7.8% with Moderna and 1.9% with J&J. The number of administered first vaccine doses dropped below 10,000 per week in early Sept, down from the peak of 440,000 in mid-May.	Procurement has been conducted exclusively via the EU. As of 14 Sept, nearly 13mn doses of vaccines delivered:  Pfizer-BioNTech – 10.1mn;  Moderna – 1.4mn;  AZ – 1.1mn;  J&J – 350,000.
Turkey	Vaccination program divided into four stages, starting with medical personnel and those over 65, followed by workers in key industries and then the 50-64,18-49 and under 18 age groups, respectively. On 31 Aug, Turkey began offering vaccinations to the 15-24 age group. Turkey aims to vaccinate all adult residents by end-Sept. On 1 Jul, it began offering an additional dose of Pfizer-BioNTech to those who had received two doses of Sinovac, amid concerns about the latter's effectiveness. On 17 Aug, Turkey announced plans to provide a second Pfizer-BioNTech dose to those who had received two doses of Sinovac.	Vaccine rollout started on 13 Jan with Sinovac. On 2 Apr, vaccinations also began with Pfizer-BioNTech vaccine. As of 15 Sept, 102.43mn doses had been administered, with 51.78mn (61.93% of population) people having received a first dose, 40.64mn (48.60% of population) at least two doses and 9.50mn (11.36% of population) three doses. After slowing in May, fresh Pfizer-BioNTech deliveries resulted in a rapid vaccine acceleration from Jun.	Sinovac – agreement for 100mn doses, of which 34.5mn delivered by 15 Sept.  Pfizer-BioNTech – agreement for 120mn doses, with 85mn delivered by 15 Sept.  Sputnik V – agreement for 50mn doses. 0.4mn doses arrived in late Jun but none had been administered as of 15 Sept.  Turkey has not joined COVAX.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Brazil	Phase 1: health workers; indigenous communities in demarcated territories; over 60s in care institutions; over 75s. Phase 2: 60-74s seniors. Phase 3: adults with comorbidities. Phase 4: education workers, homeless population, security and rescue forces, others. Phase 5: 59-18 gradually. Phase 6: teenagers with comorbidities. Phase 7: teenagers above 12.	As of 14 Sept, 138.64mn first doses have been administered (representing 65.0% of the population), while 74.29mn people (34.83% of population) are fully vaccinated.	AZ – agreement for 162mn by year-end. CoronaVac – 110mn doses by year-end. Pfizer – 200mn by year-end. J&J – 41mn doses expected in Q4. Sputnik V – Contract suspended. Covaxin – Contract suspended. COVAX – minimum 10% of population quota (42mn) doses. WHO provided 10mn doses for distribution until Aug. ButanVac – currently on trial; 100mn expected by year-end.
Argentina	Health sector personnel were first in line for vaccine, followed in descending order by age; security personnel; vulnerable and at-risk in 18-59 age range; education sector; and strategic or vulnerable groups. 12-17 year olds with comorbidities are also receiving vaccines.	Sputnik V vaccinations started on 29 Dec. As of 14 Sept, 28.8mn people (representing 64% of population) have received at least one dose, while 18.5mn people (41% of population) are fully vaccinated.	Sputnik V – agreement for 30mn doses; local production underway.  AZ – contract for 23.6mn doses, though most to be produced locally in conjunction with Mexico.  Sinopharm – agreement for 24mn doses.  CanSino – agreement for 5.4mn doses.  Pfizer – agreement for 20mn doses.  Moderna – 3.5mn doses made available from US government.  COVAX – approx. 1.9mn AZ doses delivered; government has been criticized for ordering only 20% of its entitlement.
South Korea	Vaccination campaign started on 26 Feb. Goal to vaccinate 70% of the population with two doses by Nov 2021. Vaccinations of high schools and elementary schools are underway. Vaccinations for those aged 18 to 49 have started. Booking system for vaccine appointments has been extended to speed up the pace of the vaccine rollout.	As of 15 Sept, 39.93% of population have been fully vaccinated; 26.3% of the population are only partly vaccinated. AZ jabs are administered only to the 50yrs+ age group. The number of daily confirmed Covid-19 cases is at the highest since the pandemic started 18 months ago.	President Moon plans to cooperate with the US for vaccine supply partnership (also expand partnerships to include Germany, Britain, Israel, Denmark, & Vietnam).  Korea purchased about 1.53mn doses of the Pfizer-BioNTech and Moderna vaccines - Pfizer-BioNTech (526,500) and Moderna (1.02 million) from Romania, and the first batch of Moderna doses, arrived on Sept 2.  20mn AZ doses, 67mn Pfizer-BioNTech doses, 40mn Moderna doses, 7.4mn J&J doses, 40mn Novavax doses available. 194.9mn doses available in total.
Mexico	Frontline medical workers were first in line for a vaccine followed by the over 60s age cohort and then in descending order by age. Government wants all adults to have been offered at least one dose by the end of Oct.	Vaccinations started 24 Dec. Rollout stalled mid-Jan to mid-Feb but subsequently resumed with new vaccines from wider array of suppliers. As of 12 Sept, 60.9mmn people (46.8% of population) have received at least one vaccine dose, with 39.3mn people (30.2% of population) fully inoculated.	AZ – agreement for 77.4mn doses. US has supplied Mexico with 2.7mn additional AZ doses.  Pfizer – 34mn doses ordered; 22mn delivered as of 4 Jul.  CanSino – 35mn doses agreed.  Sputnik V – agreement for 24mn doses, with local production expected soon.  COVAX – 51.5mn doses agreed; Sinovac – agreement for 20mn doses.  J&J – 1.35mn doses delivered.  Sinopharm – agreement for 12mn doses though local regulatory clearance pending.  Moderna – local regulatory clearance given in Aug.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Colombia	Plan is to vaccinate 70% of the population (35mn people) by end-2021 was reached ahead of schedule at end-Aug. Medical personnel were first in line, followed by elderly and clinically vulnerable.	Vaccination campaign started on 17 Feb with Pfizer vaccine. As of 10 Sept, 24.4mn people (47.7% of the population) have received at least one dose, while 15.7mn people (30.6% of the population) is fully vaccinated.	Pfizer-BioNTech – agreement for 15mn doses.  AZ – 10mn doses agreed.  J&J – agreement for 9mn doses.  Sinovac – agreement for 10mn doses.  Moderna – agreement for 10mn doses.  COVAX – agreement for 20mn doses.
Taiwan	Current round of <b>AZ</b> vaccinations targets two groups totaling 1mn people: those over 29 years old who previously indicated willingness to receive AZ and those over 18 years old who belong to at-risk groups.  For <b>BioNTech</b> doses, preference will be given to 12-17 year olds, with the leftover targeted to those between 18 and 22.	As of 13 Sept, 10.4mn people, or 44% of the population, had received one dose and a further 1.05mn (4.4% of the population) was fully vaccinated.  Average daily pace (7-day moving average) was 147,000 doses on 13 Sept, up from recent low 35,000 on 22 Aug but down from peak of 252,000 on 29 July.	Taiwan has received 15.3mn doses out of 81mn total doses ordered, with 12mn doses already administered, by 10 Sept.  Taiwan received 930,000 <b>BioNTech</b> doses from Shanghai Fosun Pharmaceurical on 2 Sept. A delay in mainland approval of BioNtech freed up Fosun doses for delivery to Taiwan.
Malaysia	Frontline medical workers, police, and army officials were prioritized in phase one of the vaccine rollout. Phase two, which started 19 Apr and will run through Aug, will target senior citizens, high-risk groups with co-morbidities, and the disabled. Third phase that started in May included all adults over 18. Sinovac's CoronaVac is being phased out from the program once supplies run out.	As of 13 Sept, 17.48mn (54.71% of population) have been fully vaccinated and another 4.1mn (12.83%) are still on their first shot.	Pfizer-BioNTech – 32mn doses; Sinovac – 12mn doses; AZ – 6.4mn doses via COVAX facility and another 6.4mn contracted directly; Sputnik V – 6.4mn doses; CanSino Biologics – 3.5mn doses
India	From 1 May, everyone above 18 became eligible for vaccination. From 21 Jun, all vaccines from government health facilities have been declared free of cost. The federal government – in charge of vaccinations – is allocating vaccine supplies to states according to demand assessments. All import curbs on foreign vaccines have been lifted and import duties have been waived. While the target to vaccinate everybody above 45 without comorbidities has yet to be met, the vaccination process has picked up pace. However, private hospitals say that their administrative charges are not met by the INR 150 (USD 2) cap on the fee they are allowed to charge. They claim that vaccination has slowed down as a result. There is still no decision on vaccinations for children below 18. In preparation for a possible third wave soon after the festival season in early Oct, 100,000 oxygen concentrators and 300,000 oxygen cylinders have been distributed across states.	Vaccine rollout began on 16 Jan. As of 12 Sept, 176.9mn people are fully vaccinated (12.7% of population) and 563.34mn (40.8% of the population) have received at least one dose. The rate of new Covid-19 infections remains stable after a significant decline between May and Jun. India has halted AZ vaccine exports to cater to domestic demand. Exports of Remdesivir and diversion of oxygen to non-medical uses have been banned. Some taxes on inputs in vaccine manufacturing have been lowered. Unless India steps up its daily vaccination rate, it is not going to be able to keep to its deadline of vaccinating its entire population by the end of the year. The purchase of vaccines was discussed at a meeting last week led by Prime Minister Narendra Modi.	All vaccines now free to be used in India, whether Indian or foreign, as long as they have been certified as safe in the country of origin. Import duties have been waived. However, Pfizer is negotiating an assurance of indemnity before it supplies vaccines to India. Russia's Sputnik Vis available sinceJun. Both Pfizer-BioNTech and Moderna have announced that they will supply vaccines only to federal government rather than state governments directly. Vaccine supplies have improved dramatically after the federal government took charge. However, some states are noticing supply chain glitches.
Russia	Vaccination available to all citizens 18+. Immunization of adolescents aged 12-17 is expected to be launched in Sept. More than half of the country's 85 regions announced some form of compulsory vaccination for certain occupational groups. To encourage vaccinations, government has launched a lottery.	Vaccinations started in early Dec. As of 14 Sept, an estimated 46.3mn residents (31.7% of population) had received at least one jab and 40.1mn (27.4% of population) were fully vaccinated. The pace of new vaccinations fluctuates around 130,000-160,000 doses per day, which is comparable to the period before the roll out of mandatory for certain occupational groups in June.	Russia relies solely on domestically developed vaccines: Sputnik V, EpiVac, CoviVac and Sputnik Light. A fifth domestic vaccine EpiVacCorona-N – which is an updated version of EpiVac – has been registered by the Ministry of Health in late Aug.  Authorities rule out imports of foreign vaccines.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Peru	Phase 1 focused on medical and other frontline emergency personnel, including election staff. Phase 2 focused on over 60s, those with comorbidities, and indigenous population. Caretaker government that left office end-Jul left new government with contracts for 59.1mn doses to be delivered between Aug and Dec 2021, though new government has questioned this claim.	Nov 2020 political crisis interrupted procurement process, but caretaker government that left office end-July accelerated vaccine procurement. Vaccinations using Sinopharm vaccine started 9 Feb. Pfizer-and AZ vaccines also being administered. As of 11 Sept, 12mn people (representing 36.1% of the population) have received at least one dose. 8.8mn people (26.4% of population) have received two doses.	Sinopharm – contract for 38mn doses. AZ – agreement for 14.4mn doses. Pfizer-BioNTech – original agreement for 20mn doses expanded to 32mn doses. COVAX – agreement for 13.2mn doses. Ongoing talks with J&J (5mn doses), Russia's Gamaleya Institute (for 10mn Sputnik V doses), Moderna (12mn doses), Sinovac (7mn doses), and CureVac.
Thailand	Phase one prioritizes the elderly, frontline healthcare and social workers, and those with co-morbidities. Phase two will focus on provinces with highest Covid-19 incidence. However, there are two special cases — companies will be allowed to import and distribute vaccines, and tourism areas such as Phuket are being prioritized.	Uneven supplies of locally-produced AZ vaccines sometimes slow down vaccine rollout. Sinovac and Sinopharm vaccines are now being imported. As of 13 Sept, 12.4mn (17.75%) of population have been fully vaccinated and 14.94mn (21.5%) are on their first jab. In total, 39.04% have received at least one dose.	Sinovac – 2mn, but Thailand is negotiating for an additional 6mn doses.  AZ – 61mn (imported and local joint venture).  Sinopharm - 6mn doses through private sector importation
Indonesia	Frontline healthcare workers estimated at 1.3mn have been vaccinated first, followed by security personnel and 17mn teachers; working age 15-59 are also now being vaccinated, simultaneously with the elderly. Vaccines procured by central government; distributed for free but not mandatory. Government is allowing the private sector to purchase vaccines for their employees, with these vaccinations now underway.	Second vaccination phase has started, focusing on the active workforce. As of 13 Sept, 42,33mn (15.64% of the population) have been fully vaccinated and another 31.5mn (11.64%) are on their first jab. The vaccination pace could accelerate starting in Sept as more supplies are expected.	Sinovac – 125mn doses; Pfizer-BioNTech – 100mn doses; Novavax – 100mn doses; COVAX initiative – 100mn doses; AZ – 100mn doses; private sector importation unknown.
Pakistan	Vaccination of 18-year-olds and above commenced on 3 Jun. Vaccine registration for over-40s opened on 27 Apr. Meanwhile, walk-in vaccination is available for those above 50. Those above 65 and frontline workers are still being vaccinated. Positivity rates and new infections have been rising for a month. Govt aims to vaccinate 70mn people by Dec. Many states have imposed stricter curbs on gatherings, weddings, cinema halls and schools. Among them is the region of Sindh, whose capital Karachi is facing a surge.	As of 12 Sept, 6.8% of the population had been vaccinated fully, while 22.8% of population had received at least one dose.	Emergency use permission given to AZ, Sinopharm and CanSino. Both Chinese vaccines are undergoing clinical trials. Four more vaccines in the pipeline. First COVAXvaccines have been received. Pakistan is working on developing a new nasal vaccine with CanSino, a Chinese manufacturer. On 4 Jun, it announced the successful manufacture of CanSinoBio, a single-dose vaccine produced with Chinese technology. On 21 Jun, Pfizer-BioNTech announced it will provide 13mn doses over the course of 2021.
South Africa	Plans to vaccinate 35mn people by end-2021 and 40mn by Mar 2022. Rollout started late (18 Feb) but is advancing amid vastly improved vaccine supply. Age-group-based rollout largely abandoned.	J&J and Pfizer vaccines are arriving in large quantities. Vaccination open to all adults (registration for 18-34 age cohort began on 20 Aug). Shots administered now average around 240,000 per day but official target revised upwards to 300,000. As of 13 Sept, 18.09% of population fully or partially vaccinated.	Initially reliant on COVAX/AZ vaccines, South Africa pivoted to two manufacturers, J&J and Pfizer. Large-scale deliveries began in May. J&J - 31mn doses Pfizer-BioNTech - 30mn doses Authorities now reconsidering acquiring other vaccines, including AZ. South Africa is also setting itself up as a production hub of J&J (and soon Pfizer) vaccines.
Philippines	Vaccine rollout started in Mar with high-risk groups such as healthcare workers; workers in education, social welfare agencies; law enforcement and military personnel; the poor; senior citizens; other vulnerable populations. Private sector allowed to import vaccines, though some are required to make counterpart donations. Private sector importation may make up the bulk of Q2 and Q3 vaccinations. In Manila, citizens whose work requires them to leave their homes are now being vaccinated.	As of 13 Sept, 17.07mn (15.8%) of the population are fully vaccinated and 1.62mn (1.5%) are fully vaccinated. Shortages in supply have been slowing down the vaccination rate since July, but the government is hoping for substantial Moderna and AZ deliveries in the fourth quarter.	The Philippine government has ordered 113mn doses from five vaccine manufacturers: Sinovac – 26mn doses, Sputnik V – 10mn, Moderna – 20mn, AZ – 17mn, Pfizer – 40mn. Several million Novavax doses imported by the private sector are expected in the Q4.



	Vaccination strategy	Current state of vaccine roll-out	Procurement
Egypt	777 vaccination centers across Egypt and more than 1,300 mobile teams nationwide. Govt targeting 800k daily vaccination rate. 4.5mn state employees to be vaccinated in Aug/Sept to accelerate program ahead of a possible fourth wave (early cases of Delta variant have been reported); vaccinations to become mandatory in all public institutions; university, school students, and staff (>5mn people) will be prioritized for vaccinations in preparation for academic year beginning Oct.	As of 14 Sept, Egypt has administered 11.5mn doses; 7.4% of the population has received a first dose, while only 4.9% are fully vaccinated. Egypt aims to vaccinate 10% by end-Sept; 40% by Dec; 70% by 2022. Egypt's VACSERA complex aims to produce 8 types of vaccines and serve as a vaccine hub and the largest producer of Covid-19 vaccines in MENA.	COVAX – advanced purchase agreement for 40mn doses to be provided in batches.  J&J – contract to buy 20mn doses; delivery of 261,600 doses arrived in Aug, second shipment to arrive in Sept.  Sinopharm – agreement for 40mn doses.  Pfizer-BioNTech – contracts reportedly signed for 20mn. 5.2mn doses of Pfizer and Moderna to arrive in Sept. Egypt now in talks with Moderna to manufacture the vaccine locally.  AZ – agreement for 30mn doses; 1.7mn doses arrived early Aug via COVAX, UK sent addtl 300k early Aug (via COVAX) plus another 300,000 doses in mid-Aug.  Sputnik V – 25mn have been secured. Egypt signed agreements to manufacture Sputnik V and Sinovac vaccines domestically; production of 15mn doses of Sinovac locally.
Kenya	Kenya now plans to vaccinate 10mn adults by Dec, and all adults by Jun 2022. Rollout in three phases (which may overlap):  1) frontline workers (including healthcare, teachers, army/police officers) and people aged 58+;  2) frontline workers and adults aged 18+ with comorbidities;  3) all adults aged 18+.	Rollout began 5 Mar with first 1mn AZ/COVAX doses, but supplies ran out by Jun amid India's export restrictions. Deliveries picked up in Jul via COVAX deliveries and donations (mainly from the US and EU). As of 13 Sept, 4.12% of the population had been fully or partly vaccinated.	Kenya relies on COVAX for 24mn doses but recently budgeted for additional vaccine purchases. AZ, Pfizer and Moderna donations arriving from various countries; Sinopharm vaccines also expected. 13mn J&J vaccines ordered under the African Vaccine Acquisition Task Team (AVATT) initiative are being delivered gradually.
Nigeria	Vaccination targets: 40% of population in 2021, 70% by end-2022. Healthcare personnel; people over 50; people with underlying health conditions to be prioritized. Most heavily affected states will be prioritized in allocation of doses.	First vaccine deliveries since March arrived in Aug, including 4mn doses of Moderna and 700,000 AZ vaccines from respective US and UK stockpiles via COVAX. Delivery of 7.7mn Sinopharm vaccines via COVAX expected. First small batch (178,000) of the J&J vaccine procured via AVATT arrived on 12 Aug, monthly deliveries via AVATT expected to follow up until 29.8mn doses have been supplied. As of 12 Sept, 1.91% of population had received at least one jab and 0.8% were fully vaccinated.	20% of vaccines supposed to be supplied through the COVAX initiative. Government expects total of 58mn vaccine doses from COVAX (16mn) and the AVATT (42mn). Government also expressed interest in procuring Sputnik V and/or Sinovac/Sinopharm vaccines.

© 2021 Teneo. All rights reserved. This material was produced by Teneo for use solely by the recipient. This communication is intended as general background research and is not intended to constitute advice on any particular commercial investment or trade matter or issue and should not be relied upon for such purposes. The views expressed here represent opinions as of this date and are subject to change without notice. The information has been obtained from sources believed to be reliable but no guarantees can be given as to its accuracy, completeness or reliability. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic or otherwise, without the prior consent of Teneo.